VivoSeq
Other

Hemolysis

8

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Hemolysis is an early-stage landscape with 8 programs across 6 companies. The most active players are Sanofi, Glaxo Dba Glaxosmithkline, Validus Pharmaceuticals. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

33/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1V

Validus Pharmaceuticals

1 program

ApprovedAstraZeneca logo

AstraZeneca

2 programs

PreclinicalF

Fresenius Kabi Oncology Ltd.

1 program

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

5

clinical trials

Withdrawn2 · 40%
Recruiting1 · 20%
Unknown status1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06449001·6 enrolled
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Unknown status·CCentro Medico Campinas·N/A·NCT00792779·60 enrolled
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
Completed·GSK logoGSK·Phase 1·NCT01205178·192 enrolled
HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial
Withdrawn·—·Phase 4·NCT04391231
Effects of Nitric Oxide on the Endothelium During Hemolysis.
Withdrawn·MMassachusetts General Hospital·Phase 2·NCT03748082

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)